On Thursday, BTIG made a slight adjustment to the price target for Penumbra (NYSE:), a healthcare company specializing in innovative medical devices. The new price target is set at $232.00, down from the previous $234.00, while the firm continues to recommend a Buy rating on the stock.
Penumbra recently disclosed its third-quarter financial results for 2024, revealing revenues of $301.0 million, a growth of 11.1% year-over-year, and a 10.9% increase on a constant currency basis. The company’s adjusted earnings per share (EPS) for the quarter stood at $0.85, surpassing both BTIG’s and consensus estimates which were $0.72 and $0.69, respectively.
This performance was primarily driven by a robust 14.0% growth in its Thrombectomy product line, although this was partially offset by a more modest 5.5% growth in Embolization and Access.
The company’s earnings beat was attributed to improved gross margins, which were up by 70 basis points compared to street expectations, and efficient expense management that led to a 260 basis points increase in adjusted operating margins. Penumbra has reaffirmed its full-year 2024 revenue guidance to be between $1.18 billion and $1.20 billion.
Notably, the company has adjusted its expectations for U.S. Thrombectomy growth to 24-25% year-over-year, despite witnessing declines in markets outside the United States, particularly in China.
Looking forward, Penumbra is focusing on innovation within its Comprehensive Arterial and Venous Thrombectomy (CAVT) business, with the introduction of new products such as Lightning Bolt 12 and Lightning Bolt 6X. These products are expected to enhance the company’s vascular thrombectomy and embolization offerings, particularly for venous thromboembolism (VTE) and below-the-knee occlusions.
Additionally, the recent completion of patient enrollment for the Thunderbolt study is anticipated to contribute positively to the company’s performance in the second half of 2025, especially within its Neurovascular division, which continues to experience double-digit growth.
In summary, BTIG’s outlook for Penumbra remains positive, citing the company’s steady margin expansion, market share gains in the VTE segment, introduction of new products for fiscal year 2025, and a reasonable valuation with a next twelve months enterprise value to sales ratio of 5.1x.
In other recent news, Penumbra has seen significant developments. The medical device company has completed enrollment for its THUNDER study, a crucial step towards gaining FDA clearance for its Thunderbolt computer-assisted vacuum thrombectomy system.
Needham maintained a Hold rating on Penumbra’s shares, while Piper Sandler, Canaccord Genuity, and Stifel gave positive ratings with increased price targets. Penumbra’s Q2 2024 revenue rose to $299.4 million, a 14.5% increase year-over-year, and the company has updated its 2024 revenue forecast to between $1,180 million to $1,200 million.
Additionally, Penumbra initiated a $100 million share buyback program and plans to launch three new computer-assisted vacuum thrombectomy products within the next nine months. The company also anticipates achieving over $20 million in operating savings from the Immersive Healthcare business in the next 12 months.
These are some of the recent developments involving Penumbra Inc .
InvestingPro Insights
Penumbra’s recent financial performance aligns with several key metrics and insights from InvestingPro. The company’s revenue growth of 20.89% over the last twelve months as of Q2 2024 supports the positive outlook mentioned in the article. This growth is further reinforced by a strong 14.49% quarterly revenue increase in Q2 2024, indicating consistent expansion in line with the company’s reaffirmed full-year guidance.
InvestingPro Tips highlight that Penumbra is “profitable over the last twelve months” and “analysts predict the company will be profitable this year,” which corroborates the positive earnings report discussed in the article. The company’s ability to exceed earnings estimates is reflected in its improving financial health, with InvestingPro noting that “cash flows can sufficiently cover interest payments” and the company “operates with a moderate level of debt.”
The article’s mention of Penumbra’s focus on innovation and new product introductions is particularly relevant when considering the InvestingPro Tip that the company is “trading at a high earnings multiple.” This suggests that investors may be pricing in expectations for future growth driven by these innovations.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Penumbra, providing a deeper understanding of the company’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
